Rakovina Therapeutics Announces Warrant Exercise Incentive Program

VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company” or “Rakovina”) a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery is pleased to announced that, as an update to the previously announced warrant amendments, the Company intends to implement an early exercise warrant incentive program (the “Incentive Program”) intended to encourage the exercise of up to 19,200,000 outstanding comm ...